Holy Stone Healthcare Co., Ltd. a new drug pharmaceutical company, participated in the 16^th Clinical Trials on Alzheimer’s Disease (CTAD) conference held in Boston, USA, where the advancements of the self-developed Alzheimer’s Disease new drug ND108E was presented. During the conference, experts provided valuable feedback on the efficacy of ND108E addressing the cognitive impairment and memory restoration. Noteworthy, discussions were centered around the challenges encountered, potential indications, and the strategic clinical design of ND108E. Furthermore, dialogues took place regarding potential collaborations, and explored opportunities for future partnerships with representatives of Big pharm.

CTAD conference stands as a pivotal platform for unveiling clinical outcomes of AD treatments. Clinical results of Aducanumab and Lecanemab were both presented in CTAD. ND108E was a new drug of hyaluronic acid–17-estradiol conjugate that restore recognition functions, and reduce the risk of estrogen-supplement-related side effects. The research findings of ND108E were presented in Translation Research section where preclinical results were discussed in depth.

Our research results included,

1. ND108E can pass through the blood–brain barrier (BBB) to the hippocampus.
2. ND108E can restore the learning and memory functions caused by E2 deficiency.
3. ND108E can restore the spine number caused by E2 deficiency.
4. The mode of actions of ND108E were enhance mitochondria activity, promote Amyloid precursor protein to non-amyloid pathway to reduce amyloid b, and activate PI3K/Akt pathway to inhibit phosphorylation of Tau

Taken together, ND108E can enhance neuron cell activity, spine growth and increase spine number that restore neuron transmission and cognition functions. In the meantime, Amyloid b reduction and Tau phosphorylation inhibition can reduce the damage of neuron cells.

The officially presentation of ND108E research results at CTAD garnered attention from experts discussed from different aspects. Compared with Aducanumab and Lecanemab, ND108E demonstrated superior safety profile than both antibody drugs, and further evaluation involving plaque reduction is required for a comprehensive comparison. The ND108E poster attracted representatives of Biogen, Eisai, AbbVie who showed interest in the detail of ND108E research, and request for publication and reference to evaluate the possibility of collaboration.